CHABMAP (Cyanobacterial Harmful Algal Bloom Mapping and Analyses Platform) technology automates the quantification of toxic CyanoHABs exposure epochs for any waterbody.

具体目标#1：实施时空氰化氢化合物暴露纪元指标 ·融合多尺度和不同类型的卫星遥感平台，实现自动检索 空间和时间，以得出氰化氢暴露指标。我们将全面构建企业软件 自动协调和融合NASA的Landsat-8 Oli和ESA的Sentinel-2以及 Sentinel-3卫星平台提供长期(1984年至今)中等空间分辨率 (30米像素)和高时间频率氰化赤潮暴露指标(蓝藻 浓度，颜色，溶解有机物，总悬浮固体，漂浮藻类指数， 叶绿素-a浓度和毒素)。决策支持工具自动执行纪元综合，以 了解神经退行性疾病的潜伏期和暴露诱因。 具体目标#2：扩展按需CHABMAP商业产品服务 ·使用BigData云扩展和实施CHABMAP数据服务，实现无限可扩展性 技术。这个目标涉及三个主要的开发工作：调整我们的专有 将地理空间图像和处理系统(GIPS)功能扩展到AWS可部署的自动扩展 集群、创建用户界面和与之交互的应用程序编程接口(API) 这些服务，以及对基本GIPS框架的增强，以促进相互通信 在远程启用GIPS的归档和云处理流之间。这包括 创建可部署的计算实例、优化计算和并行化 针对AWS部署，优化中间件的临时和长期存储 产品，并优化与最终用户的通信和数据传输。归根结底，这 AIM将允许评估和监测任何水体或 地球上的一个地区(即北美洲)。 具体目标3：与公共卫生合作伙伴一起执行风险评估框架 ·我们将与克利夫兰诊所、达特茅斯希区柯克医疗中心合作， 迈阿密大学、麦格理大学、美国国立卫生研究院神经肌肉疾病研究部和 CDC有毒物质和疾病登记处(国家ALS登记处)评估其作用 使用患者将氰化血红蛋白暴露作为肌萎缩侧索硬化症(ALS)的风险因素， 跨越不同环境和地理位置的基于临床和基于人群的控制。每个应用程序 最终用户拥有持续的风险评估框架(例如，基因-环境、居住历史 机器学习、生态流行病学、分子生物学)，我们的CHABMAP技术将 整合暴露时期指标，以了解病因或ALS，并支持药物发现。 建议的创新 CHABMAP技术自动量化有毒蓝藻有害藻华(CHAB) 过去40年世界上任何水体或集水区的多尺度曝光纪元 协调的卫星。我们使用定制和专有技术与BigData软件相结合来 生成历史曝光(“exposome”)配置文件，并提供决策支持工具服务 近乎实时的CHAB监控。在第二阶段及以后，我们与世界专家合作，将 我们的商业产品和服务进入神经退行性疾病基因环境(GxE)风险 评估框架。 建议的产品、服务、结果 ·与环境机构合作伙伴共同制定CHAB的历史暴露测量 ·在多个独立研究区域评估氰化血红蛋白是肌萎缩侧索硬化症的风险因素 ·CHABMAP按需分析即服务平台在第二阶段结束时运行 ·支持神经紊乱和疾病的病因学发现和药物开发

Specific Aim #1: Operationalize spatio-temporal CyanoHAB exposure epoch metrics • Fuse multi-scale and disparate satellite remote sensing platforms and automate retrievals over space and time to derive CyanoHAB exposure metrics. We will build enterprise software to fully automate the harmonization and fusion of NASA’s Landsat-8 OLI and ESA’s Sentinel-2 and Sentinel-3 satellite platforms to provide long-term (1984-present) moderate spatial resolution (30meter pixels) and high temporal frequency CyanoHAB exposure metrics (Cyanobacteria Intensity, Color Dissolved Organic Matter, Total Suspended Solids, Floating Algae Index, Chlorophyll-a Concentration, & toxins). The decision support tool automates epoch synthesis to understand incubation periods and exposure triggers for neurodegenerative diseases. Specific Aim #2: Scale on-demand CHABMAP commercial product services • Scale and implement CHABMAP data services for infinite scalability using BigData cloud technologies. This Aim involves three main development efforts: adapting our proprietary Geospatial Image and Processing System (GIPS) capabilities to an AWS-deployable auto-scaling cluster, creation of user interfaces and application programming interfaces (APIs) to interact with these services, and enhancements to the base GIPS framework to facilitate intercommunication between remote GIPS-enabled archives and the cloud processing streams. This includes the creation of deployable compute instances, optimization of computation and parallelization specific to AWS deployment, optimization of temporary and long-term storage of intermediate products, and optimization of communication and data transfer with end users. Ultimately, this Aim will allow for the assessment and monitoring of CyanoHAB conditions for any waterbody or region (i.e., North America) on the planet. Specific Aim #3: Execute risk assessment frameworks with public health partners • We will work in partnership with Cleveland Clinic, Dartmouth Hitchcock Medical Center, University of Miami, Macquarie University, NIH’s Neuromuscular Diseases Research Section and CDC’s Agency for Toxic Substances and Disease Registry (National ALS Registry) to assess the role of CyanoHABs exposure as a risk factor for Amyotrophic lateral sclerosis (ALS) using patients, clinic-, and population-based controls across diverse settings and geographies. Each application end user has ongoing risk assessment frameworks (i.e., Gene-Environment, Residential History Machine Learning, eco-epidemiological, molecular biology) which our CHABMAP technology will integrate exposure epoch metrics to understand the etiology or ALS and support drug discovery. Proposed Innovation CHABMAP technology automates the quantification of toxic Cyanobacterial Harmful Algal Bloom (CHAB) exposure epochs for any waterbody or catchment in the world for the past four decades using multi-scale harmonized satellites. We use custom and proprietary techniques combined with BigData software to generate historical exposure (“exposome”) profiles as well provide Decision Support Tools services for CHAB monitoring in near-real time. During Phase 2 and beyond we work with world experts to integrate our commercial products and services into neurodegenerative disease Gene-Environment (GxE) risk assessment frameworks. Proposed Products, Services, Outcomes • Develop historical CHAB exposure measurements working with environmental agency partners • Assessment of CyanoHABs as a risk factor for ALS across multiple, independent study regions • CHABMAP on-demand Analytics-as-a-Service platform operating at end of Phase 2 • Support discovery of etiology and drug development for neurological disorders and diseases